NULOJIX

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Netherlands, Poland, Spain, UK.

Active ingredients

The drug NULOJIX contains one active pharmaceutical ingredient (API):

1	Belatacept UNII E3B2GI648A - BELATACEPT
	Belatacept, a modified form of CTLA4-Ig, binds CD80 and CD86 more avidly than the parent CTLA4-Ig molecule from which it is derived. This increased avidity provides a level of immunosuppression that is necessary for preventing immune-mediated allograft failure and dysfunction. Belatacept blocks CD28 mediated co-stimulation of T cells inhibiting their activation.
	Read more about Belatacept

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NULOJIX Powder for concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AA28		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants
Discover more medicines within L04AA28

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1533215, 1533226
ES	Centro de información online de medicamentos de la AEMPS	11694002
FR	Base de données publique des médicaments	69597619
GB	Medicines & Healthcare Products Regulatory Agency	194635, 194636
IT	Agenzia del Farmaco	041282017, 041282029
LT	Valstybinė vaistų kontrolės tarnyba	1061230, 1061231
NL	Z-Index G-Standaard, PRK	101044
PL	Rejestru Produktów Leczniczych	100247950
US	FDA, National Drug Code	0003-0371